- Flora’s collaboration with Highsman seeks to elevate both Highsman and Vessel, Flora’s accessories brand, thereby inspiring greatness and creating an experience worth sharing
- The company’s acquisition of Masaya allows it to deliver on its promise to invest in safe, thorough, and cutting-edge cannabis research
- Flora’s product launch on Amazon.co.uk marks a big step in operations expansion in Europe
The first half of 2022 has been successful for Flora Growth (NASDAQ: FLGC). At the beginning of the year, the company’s management noted how the cannabis sector was ripe for the picking. They noted how great brands and cost advantages are optimal traits for the company’s long-term market leadership and return on investment (“ROI”), emphasizing the opportunities ahead (https://cnw.fm/MnWUI).
Flora Growth has since partnered with Highsman, a cannabis lifestyle brand built on an appreciation for greatness, founded by former NFL running back Ricky Williams. The collaboration seeks to elevate Highsman and Flora’s cannabis accessories brand, Vessel, (https://cnw.fm/9HXBx)
While announcing the collaboration, James Choe, Flora Growth Chief Strategy Officer (“CSO”) and President of Vessel noted that “Ricky’s story personifies the authenticity and individuality that exists at the core of Vessel, and this collaboration is a true representation of the freedom to be original.”
Following the announcement of the Ricky Williams collaboration, flora announced the acquisition of CBD Brand Masaya. Flora entered into an agreement with Dr. Annabelle Manalo-Morgan, a leading cell biologist, to acquire her brand, along with its patent-pending CBD formulations, which are made up of potent CBD oil and are 100% THC-free (https://cnw.fm/jRF7l).
Upon acquisition, Masaya became an owned Flora brand sold in the United States and the first offering from Flora Life Sciences. It is also projected that the patent-pending formulation, Masaya Pure, will be used in Flora’s current clinical trials with the University of Manchester in the UK. The doctor now serves on Flora’s Board of Directors as the company’s Scientific Advisor. She is also responsible for leading Flora’s global research initiatives, including the ongoing clinical trial on the use of cannabinoids with patients with fibromyalgia.
“We are excited to announce the acquisition of Masaya. The brand’s formulation was developed by Dr. Annabelle for her son and has since been used by thousands of consumers,” noted Luis Merchan, Flora’s Chairman and Chief Executive Officer (“CEO”).
“This acquisition allows us to deliver on our promise to invest in safe, thorough, cutting-edge scientific research that can bring meaningful change via an efficacious and accessible product offering for the people worldwide,” he added.
At the close of May, Flora announced that its wholly-owned subsidiary, JustCBD, would be launching its line of Novel Foods registered CBD products on Amazon.co.uk. Set to launch on the e-commerce store in June 2022, this move would see customers in the UK access JustCBD’s best-selling gummies and tinctures (https://cnw.fm/RIVWM).
This launch marked a significant step in Flora’s operations expansion in Europe. In addition, it showed the company’s commitment to delivering quality cannabis-related products to customers aiming to improve their health and wellness.
“With health and wellness playing an increasingly important role in customers’ lives, we are excited to increase the selection of quality CBD products offered to Amazon customers in the UK,” noted Hussein Rakine, JustCBD’s CEO.
“The JustCBD team looks forward to working closely with Amazon to expand our product offering to other countries as our partnership and brand presence in the United Kingdom grows,” he added.
Going into the second half of the 2022 calendar year, Flora Growth seeks to aggressively pursue the goals set at the beginning of the year, further expanding its market reach and growing its product line and customer numbers.
For more information, visit the company’s website at www.FloraGrowth.com.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC
About CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.canadiancannabiswire.com
Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire (CNW)
Toronto, Ontario
www.canadiancannabiswire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com
CanadianCannabisWire is part of the InvestorBrandNetwork.
